Nurix Therapeutics
NRIX
128 hedge funds and large institutions have $352M invested in Nurix Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 41 increasing their positions, 51 reducing their positions, and 10 closing their positions.
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
18% more call options, than puts
Call options by funds: $104K | Put options by funds: $88K
2% more funds holding
Funds holding: 126 → 128 (+2)
1.02% more ownership
Funds ownership: 91.97% → 92.99% (+1%)
19% less capital invested
Capital invested by funds: $436M → $352M (-$83.2M)
20% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.43M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.03M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.87M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.83M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.25M |
| 2 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$3.14M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.79M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.38M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$1.3M |
NRIX Hedge Fund Activity: Q3 2023 in Review
128 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2023, worth a combined $352M — down 19% from $436M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NRIX positions and 10 closed out — a net gain of 3 holders — while 41 added to existing stakes and 51 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $7.43M. The largest seller was Millennium Management, cutting an estimated $3.25M.
- 128 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2023, up from 126 in Q2 2023.
- Funds reported $352M of Nurix Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
- 13 funds opened new Nurix Therapeutics positions in Q3 2023 and 10 closed out, a net change of +3 holders.
- The largest Nurix Therapeutics buyer in Q3 2023 was Soleus Capital Management, an estimated $7.43M added.
- The largest Nurix Therapeutics seller in Q3 2023 was Millennium Management, an estimated $3.25M sold.
Based on aggregated 13F filings for Q3 2023.